Skip to main content
Ragupathy Renganathan
Ragupathy Renganathan
Pharma Hub

Interview Questions

Pharma Regulatory Affairs Interview Questions and Answers

Regulatory Affairs interviews test whether you can translate technical data into a defendable submission. Panels probe CTD module placement, the difference between a variation and a prior-approval supplement, and how you would respond to a deficiency letter.

The model answers below name the guideline and the practical consequence, which is what reviewers listen for.

10 questions with model answers · Updated for current GMP and ICH expectations

What this round covers

  • CTD and eCTD structure
  • ANDA, NDA and DMF
  • Variations and post-approval changes
  • Agency queries and deficiency responses
  • Labelling and artwork control

10 Regulatory Affairs interview questions with answers

  1. Q1CTDBeginner

    What does CTD stand for?

    Model answer: The CTD is the harmonised ICH dossier format with five modules used across regions.

    • Module 1 regional
    • Modules 2-5 common
    • eCTD electronic format
  2. Q2CTDBeginner

    Which CTD module contains regional administrative information?

    Model answer: Module 1 is region specific and not part of the harmonised CTD.

    • Application forms
    • Labelling
    • Regional requirements
  3. Q3CTDBeginner

    Quality data (drug substance and product) resides in:

    Model answer: Module 3 holds the full quality/CMC data; Module 2.3 holds the Quality Overall Summary.

    • 3.2.S and 3.2.P
    • QOS in 2.3
    • Granularity rules
  4. Q4CTDBeginner

    Non-clinical study reports are placed in:

    Model answer: Module 4 contains toxicology and pharmacology study reports.

    • GLP compliance
    • Study report structure
    • Overview in 2.4
  5. Q5USBeginner

    An ANDA is filed for:

    Model answer: ANDAs rely on demonstrating bioequivalence to the Reference Listed Drug.

    • BE studies
    • Patent certifications
    • 505(j) pathway
  6. Q6USAdvanced

    Paragraph IV certification asserts that:

    Model answer: A Para IV certification challenges the listed patent and may trigger litigation and 180-day exclusivity.

    • 30-month stay
    • First filer exclusivity
    • Notice letter
  7. Q7USAdvanced

    505(b)(2) applications rely partly on:

    Model answer: The 505(b)(2) pathway permits reliance on data not developed by the applicant.

    • Bridging studies
    • Patent certification
    • Suitable for modified products
  8. Q8DMFIntermediate

    A Drug Master File Type II covers:

    Model answer: Type II DMFs contain API manufacturing, controls and stability information.

    • Letter of authorisation
    • Completeness assessment
    • GDUFA fees
  9. Q9DMFIntermediate

    A Letter of Authorisation is needed because:

    Model answer: The DMF holder authorises the agency to reference confidential information for a specific applicant.

    • Named applicant
    • Copy to applicant
    • Update on changes
  10. Q10ICHBeginner

    Which ICH guideline covers stability testing of new drug substances and products?

    Model answer: ICH Q1A(R2) sets the core stability requirements including storage conditions and batch numbers.

    • Long-term/accelerated
    • Bracketing and matrixing
    • Zones

Rehearse these answers out loud

The remaining 88 Regulatory Affairs questions run inside the AI Interview Simulator, which adapts difficulty to your answers and scores your response against the same key points shown above. Creating a free account takes a minute — no card required.

Open Interview Simulator Create a free account

Other pharma interview departments